
|Videos|August 6, 2021
Dr. Ketan K. Badani discusses the significance of PSMA agents
Author(s)Urology Times staff
“I think as these [advanced imaging] agents come out, we're going to see more and more data on this topic,” says Ketan K. Badani, MD.
Advertisement
In this video, Ketan K. Badani, MD, shares a key takeaway in prostate cancer from the 2021 ASCO annual meeting. Badani is a professor of urology at Icahn School of Medicine at Mount Sinai, vice chairman of urology and robotic operations at Mount Sinai Health System, director of robotic surgery at Mount Sinai West, and the director of the Comprehensive Kidney Cancer Program At Mount Sinai Health System, New York.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
PSMA-PET/CT–guided salvage radiotherapy yields favorable outcomes after prostatectomy
2
National Cancer Prevention Month: Prostate Cancer Screening FAQs for Clinicians
3
Christopher Filson, MD, on using CxBladder Triage to risk-align cystoscopy in microhematuria
4
How anesthesia-free stone treatment may shift urology practice
5






